The findings underscore the substantial burden of steatotic liver disease and highlight the importance of recognizing its distinct subtypes in clinical practice.
The findings underscore the substantial burden of steatotic liver disease and highlight the importance of recognizing its distinct subtypes in clinical practice.
The study synthesizes data from 18 studies and more than half a million subjects to better characterize how nonbiologic factors contribute to MASLD burden.
The study synthesizes data from 18 studies and more than half a million subjects to better characterize how nonbiologic factors contribute to MASLD burden.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new update from the US Multi-Society Task Force on Colorectal Cancer revises and refines recommendations for optimizing bowel preparation in colonoscopy.
A new update from the US Multi-Society Task Force on Colorectal Cancer revises and refines recommendations for optimizing bowel preparation in colonoscopy.
For practicing gastroenterologists, these results highlight the importance of proactive risk assessment and coordinated care strategies in MASLD populations, beyond liver-specific endpoints.
For practicing gastroenterologists, these results highlight the importance of proactive risk assessment and coordinated care strategies in MASLD populations, beyond liver-specific endpoints.
The study analyzed data from the Research Patient Data Registry between 2000 and 2023, focusing on patients aged 40 and older with a baseline FIB-4 score of 1.3 or higher.
The study analyzed data from the Research Patient Data Registry between 2000 and 2023, focusing on patients aged 40 and older with a baseline FIB-4 score of 1.3 or higher.
The TEMPO trial enrolled 40,000 adults aged 50–74 years and randomly assigned them to one of eight groups, testing combinations of a planning tool and deadline prompts of varying lengths.
The TEMPO trial enrolled 40,000 adults aged 50–74 years and randomly assigned them to one of eight groups, testing combinations of a planning tool and deadline prompts of varying lengths.
The study evaluated 34,647 symptomatic patients who submitted contemporaneous f-Hb and full blood count samples between December 2015 and December 2019.
The study evaluated 34,647 symptomatic patients who submitted contemporaneous f-Hb and full blood count samples between December 2015 and December 2019.
